The Human Variable 

POTS clinical trials often fail by treating a multi-system disorder as a narrow cardiovascular condition. This CYNAERA framework outlines stabilization, phenotype stratification, adaptive design, and real-world endpoints to improve outcomes and reduce trial failure.

CDF-Peds-LC™ was developed as CYNAERA’s proposed Composite Diagnostic Fingerprint for Pediatric Long COVID. It is a structured recognition and tracking framework designed to identify probable pediatric Long COVID through five interlocking domains: post-infection onset, multisystem symptom burden, post-exertional patterning, functional disruption, and fluctuation or relapse over time.

AI-driven environmental amplification interacts with a large and growing population of individuals with infection-associated chronic conditions (e.g., Long COVID, ME/CFS), who exhibit heightened physiological sensitivity to environmental triggers such as fine particulate matter (PM₂.₅), heat stress, and atmospheric instability. If you want an alternate tone that leans slightly more policy-facing:

The Moral Adinig Method™ is a harm-aware AI training framework that embeds contextual reasoning, moral memory, and relational identity scaffolding to improve safety and reliability. Cross-model evaluations show reduced harmful recommendations, stronger bias translation into protective guidance, and improved decision integrity in complex, high-risk environments without modifying model weights. If you want an alternate tone that leans slightly more policy-facing:

The Aligned Intelligence Method (AIM™) is a human-readable, machine-interpretable knowledge framework that embeds interpretive guardrails directly into source documents. AIM aligns lived patterns, longitudinal data, domain reasoning, and environmental context into unified analytic references that support both human understanding and consistent AI interpretation.

Autoimmune and immune-mediated illness rarely begins with a clear diagnosis. More often, it begins with patterns that repeat long before medicine assigns a label. Symptoms rise, fall, and cluster. Tests come back “normal.” Patients are told to wait, monitor, or manage symptoms. Yet the immune system is already behaving abnormally. This paper refers to that early, overlooked phase as Stage Zero autoimmune illness.